833 related articles for article (PubMed ID: 22440742)
1. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
2. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
3. Stage IB nonsmall cell lung cancers: are they all the same?
Jones DR; Daniel TM; Denlinger CE; Rundall BK; Smolkin ME; Wick MR
Ann Thorac Surg; 2006 Jun; 81(6):1958-62; discussion 1962. PubMed ID: 16731113
[TBL] [Abstract][Full Text] [Related]
4. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
Pfannschmidt J; Muley T; Hoffmann H; Bülzebruck H; Dienemann H
Dtsch Med Wochenschr; 2006 Nov; 131(47):2643-8. PubMed ID: 17109272
[TBL] [Abstract][Full Text] [Related]
5. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
[TBL] [Abstract][Full Text] [Related]
6. Validation of pN2 sub-classifications in patients with pathological stage IIIA N2 non-small cell lung cancer.
Nakagiri T; Sawabata N; Funaki S; Inoue M; Kadota Y; Shintani Y; Okumura M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):733-8. PubMed ID: 21297135
[TBL] [Abstract][Full Text] [Related]
7. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer.
Liu H; Zhang T; Li X; Huang J; Wu B; Huang X; Zhou Y; Zhu J; Hou J
Cancer Sci; 2008 Nov; 99(11):2185-92. PubMed ID: 18823373
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.
Rades D; Setter C; Dahl O; Schild SE; Noack F
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):442-7. PubMed ID: 20950963
[TBL] [Abstract][Full Text] [Related]
10. A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma.
Tsai MF; Wang CC; Chang GC; Chen CY; Chen HY; Cheng CL; Yang YP; Wu CY; Shih FY; Liu CC; Lin HP; Jou YS; Lin SC; Lin CW; Chen WJ; Chan WK; Chen JJ; Yang PC
J Natl Cancer Inst; 2006 Jun; 98(12):825-38. PubMed ID: 16788156
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of Id-1 expression in patients with resectable esophageal squamous cell carcinoma.
Luo KJ; Wen J; Xie X; Fu JH; Luo RZ; Wu QL; Hu Y
Ann Thorac Surg; 2012 May; 93(5):1682-8. PubMed ID: 22480390
[TBL] [Abstract][Full Text] [Related]
12. [Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].
Li Y; Sun BS; Zhang ZF; Zhang LM; Wang CL
Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(24):1682-6. PubMed ID: 21914316
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular predictors of recurrence in stage I non-small cell lung cancer.
Starnes SL; Pathrose P; Wang J; Succop P; Morris JC; Bridges J; Kupert EY; Anderson M
Ann Thorac Surg; 2012 May; 93(5):1606-12. PubMed ID: 22440368
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma.
Cao X; Li Y; Luo RZ; He LR; Yang J; Zeng MS; Wen ZS
Ann Thorac Surg; 2012 May; 93(5):1674-80. PubMed ID: 22429674
[TBL] [Abstract][Full Text] [Related]
15. Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer.
Augustin F; Fiegl M; Schmid T; Pomme G; Sterlacci W; Tzankov A
J Clin Pathol; 2015 May; 68(5):368-73. PubMed ID: 25731190
[TBL] [Abstract][Full Text] [Related]
16. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy.
Saji H; Tsuboi M; Matsubayashi J; Miyajima K; Shimada Y; Imai K; Kato Y; Usuda J; Kajiwara N; Uchida O; Ohira T; Hirano T; Mukai K; Kato H; Ikeda N
Anticancer Drugs; 2010 Jan; 21(1):89-93. PubMed ID: 19770636
[TBL] [Abstract][Full Text] [Related]
17. Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study.
Papotti M; Kalebic T; Volante M; Chiusa L; Bacillo E; Cappia S; Lausi P; Novello S; Borasio P; Scagliotti GV
J Clin Oncol; 2006 Oct; 24(30):4818-24. PubMed ID: 17050866
[TBL] [Abstract][Full Text] [Related]
18. The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non-small cell lung cancer.
Yoon KA; Yoon H; Park S; Jang HJ; Zo JI; Lee HS; Lee JS
J Thorac Cardiovasc Surg; 2012 Oct; 144(4):794-807. PubMed ID: 22818121
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
[TBL] [Abstract][Full Text] [Related]
20. High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer.
Feng J; Zhang X; Zhu H; Wang X; Ni S; Huang J
Am J Clin Pathol; 2012 Aug; 138(2):230-5. PubMed ID: 22904134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
